Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
The veterinary vaccine producer raised a modest $6.9 million in its New York listing by selling just 3% of its shares, as it diversifies into the household pets market Key…
Recent Articles
RELATED ARTICLES
-
Dispute over Covid vaccines casts doubt on Clover Bio recovery
2197.HK -
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
- Aging population, declining birthrate fluff up China’s ‘Furry Economy’
-
Dogness limps ahead as investors chase its stock
DOGZ.US
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
- Plenty of room for growth in China’s hair transplant market
